Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JACOB: Joint Administration of cDNA for TP53, checkpOint Inhibition and Boost/Hypofractionated Radiation. A Phase 0/1 Study in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816 is registered in ClinicalTrials.gov with Children's National Research Institute as lead sponsor.

NCT NCT07017816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07017816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JACOB: Joint Administration of cDNA for TP53, checkpOint Inhibition and Boost/Hypofractionated Radiation. A Phase 0/1 Study in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Lead sponsor
Children's National Research Institute
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2025
Completion date
May 1, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrt recurrent, cns malignancies, embryonal neoplasm, ependymoma recurrent, high grade gliomas, medulloblastoma recurrent, pineoblastoma